Department of Cellular Immunotherapy

2025

• Couto P S, Stibbs D J, Springuel P, Schultz U, Effenberger M, Goldrick S, Navarro-Velázquez S, Juan M, Herbst L, Nießing B, Mestermann K, Sanges C, Hudecek M, Rafiq Q A. Impact of serum/xeno-free medium and cytokine supplementation on CAR-T cell therapy manufacturing in stirred tank bioreactors. Biotechnol J. 2025, 20 (9): e70114. doi: 10.1002/biot.70114
• De Angelis B, D'Amore ML, Lecot P, Neininger K, Lorrain M, Gambotti L, Dreuillet C, Courcault E, Chatterjee S, Delgado J, Galy A, Franz P, Rodriguez-Madoz JR, Cabrerizo Y, Richter A, Girvalaki C, Noviello M, Tassi E, Sanges C, Luu M, Hudecek M, Kremer A, Locatelli F, Negre H, Quintarelli C. European survey on CAR T-Cell analytical methods from apheresis to post-infusion immunomonitoring. Front Immunol. 2025 Apr 24;16:1567582. doi: 10.3389/fimmu.2025.1567582. eCollection 2025. PMID: 40342422
• Jaeckel E, Friedman SL, Hudecek M, Protzer U. Chimeric Antigen Receptor (CAR) T-cell Therapy: Engineering Immune Cells To Treat Liver Diseases. J Hepatol. 2025 Jun 20:S0168-8278(25)02274-3. doi: 10.1016/j.jhep.2025.06.007. Online ahead of print. PMID: 40545042
• Nguyen TT, Ho P, Staudt S, Gregoire C, Ziegler-Martin K, Jassin M, Block A, Hudecek M, Melenhorst JJ, Caers J, Luu M. Fine tuning towards the next generation of engineered T cells. Nat Biomed Eng. 2025 Oct 10. doi: 10.1038/s41551-025-01492-8. Online ahead of print.
• Pennings E R, Spanjaart A M, Thielen F W, Oerlemans S, Fleischer A, Sanges C, Gomes Da Silva M, Cabrerizo Y, Lecot P, Roux-Opstaele L, Dreuillet C, Gonzalez-Marcano E, Millán O, Jaeger U, Delgado J, Luu M, Huber B, Lorrain M, Galhardas Pina M, Kremer A, Bolanos N, Clavreul S, Nier S, Liu R D K, Lissenberg-Witte B I, Anguille S, Robin M, Morris E C, Sureda A, Préau M, Pannard M, Bock G H de, Wagers S S, Trebeden-Negre H, Maucort-Boulch D, Hudecek M, Uyl-de Groot C A, Kersten M. Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in Europe. Blood Adv. 2025, 9 (24): 6380-6393. doi: 10.1182/bloodadvances.2025017081
• Petri K, D'Ippolito E, Künkele A, Köhl U, Busch DH, Einsele H, Hudecek M. Next-generation T cell immunotherapies engineered with CRISPR base and prime editing: challenges and opportunities. Nat Rev Clin Oncol. 2025 Sep 19. doi: 10.1038/s41571-025-01072-4. Online ahead of print.
• Rade M, Fandrei D, Kreuz M, Seiffert S, Grahnert A, Friedrich M, Wiemers T, Born P, Fischer L, Weidner H, Hofbauer LC, Baber R, Wang SY, Bach E, Hoffmann S, Scolnick J, Friedrich M, Keramati F, Brazda P, Sebestyen Z, Kuball J, Alb M, Scheller L, Hudecek M, Einsele H, Metzeler KH, Herling M, Herling CD, Jentzsch M, Franke GN, Boldt A, Köhl U, Platzbecker U, Vucinic V, Reiche K, Merz M. A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myeloma. Cancer Cell. 2025, S1535-6108 (25) 00490-8. doi: 10.1016/j.ccell.2025.10.014
• Reiche K, Weirauch U, Kreuz M, Fischer L, Gras L, Neumuth T, Platzbecker U, Köhl U, Demlova R, Kremer A, Fröhlich H, Franke S, Merz M; CERTAINTY Consortium. Virtual twins for personalised CAR T-cell therapy in myeloma. Lancet Haematol., 2025 Jul;12(7):e490-e491. doi: 10.1016/S2352-3026(25)00170-X
• Riester Z, Surowka M, Seifert N, Darowski D, Ghosh A, Spieler P, Weber J, Gianotti R, Freitag F, Alb M, Nerreter T, Gerhard-Hartmann E, Rosenwald A, Sauer M, Moessner E, Einsele H, Ferrara-Koller C, Klein C, Hudecek M, Danhof S. Co-expression of an adapter CAR retains efficacy of CAR T cells after single and dual antigen loss in lymphoma. Mol Ther. 2025, S1525-0016(25)00867-6. doi: 10.1016/j.ymthe.2025.10.046
• Scheller L, Zhou X, Loeffler-Wirth H, Kreuz M, Kadel SK, Schimanski S, Schulze H, Ruckdeschel A, Eisele F, Konetzki V, Jornet Culubret M, Merz M, Mersi J, Waldschmidt J, Danhof S, Köhl U, Kortüm KM, Rasche L, Einsele H, Düll J, Topp MS, Hudecek M, Reiche K, Alb M. Endothelial dysfunction and proinflammatory state determine severe hematotoxicity and inferior outcome of CAR-T therapy. Hemasphere. 2025, 9 (12): e70267. doi: 10.1002/hem3.70267
• Tony L T, Stabile A, Schauer M P, Hudecek M, Weber J. CAR-T cell therapy for solid tumors. Transfus Med Hemother. 2025, 52 (1): 96–108. doi: 10.1159/000542438
• Weber J, Rade M, Michael J, Tony L T, Freitag F, Spieler P, Müller C, Kalogirou C, Mainz L, Lehmann J, Klopfleisch R, Rosenfeldt M T, Danhof S, Kortüm K M, Köhl U, Einsele H, Rader C, Reiche K, Nerreter T, Hudecek M. ROR2-specific CAR T cells are effective against hematologic and solid tumors and well tolerated in mice. Cell Rep Med. 2025, 6 (10): 102400. doi: 10.1016/j.xcrm.2025.102400
• Wegner V D, Feile A, Alb M, Hudecek M, Hewitt P, Mosig A S. Short-chain fatty acids modulate anti-ROR1 CAR T-cell function and exhaustion in an intestinal adenocarcinoma-on-chip model. Adv Healthc Mater. 2025 May;14(13):e2405003. Epub 2025 Apr 18. doi: 10.1002/adhm.202405003
• Weirauch U, Kreuz M, Birkenbihl C, Alb M, Quaranta M, Calzone L, Orozco-Ruiz S, Binder S, Fischer L, Clavreul S, Maguri M, Ferle M, Rade M, Azarias G, Hydren J R, Jamarik J, Schwarz D, Sebestyen Z, Kuball J, Popp G, Antoine C, Knockaert M, Schoeder C T, Fandrei D, Sanges C, Radvilas V, Gagelmann N, Rückert M, Penack O, Fricke S, Schmidt A, Ward C, Steinbeisser C, Van Gyseghem J-M, Niarakis A, Garderet L, Hudecek M, Neumuth T, Platzbecker U, Köhl U, Demlova R, Kremer A, Franke S, Fröhlich H, Merz M, Reiche K, CERTAINTY Consortium. Design specifications for biomedical virtual twins in engineered adoptive cellular immunotherapies. NPJ Digit Med. 2025, 8 (1): 493. doi: 10.1038/s41746-025-01809-6

2024

• Alb M, Reiche K, Rade M, Sewald K, Loskill P, Cipriano M, Maulana TI, D van der Meer A, Weener HJ, Clerbaux LA, Fogal B, Patel N, Adkins K, Lund E, Perkins E, Cooper C, van den Brulle J, Morgan H, Rubic-Schneider T, Ling H, DiPetrillo K, Moggs J, Köhl U, Hudecek M. Novel strategies to assess cytokine release mediated by chimeric antigen receptor T cells based on the adverse outcome pathway concept. J Immunotoxicol.,2024 Oct;21(sup1):S13-S28. doi: 10.1080/1547691X.2024.2345158. Epub 2024 Dec 10.
• Maulana TI, Teufel C, Cipriano M, Roosz J, Lazarevski L, van den Hil F, Scheller L, Orlova V, Koch A, Hudecek M, Alb M, Loskill P. Breast cancer-on-chip for patient-specific efficacy and safety testing of CAR-T cells. Cell Stem Cell, 2024 Jul 5;31(7):989-1002.e9. doi: 10.1016/j.stem.2024.04.018. Epub 2024 May 15.
• Mazein A, Shoaib M, Alb M, Sakellariou C, Sommer C, Sewald K, Reiche K, Gogesch P, Roser LA, Ortega Iannazzo S, Sheth S, Schiffmann S, Waibler Z, Neuhaus V, Dehmel S, Satagopam V, Schneider R, Ostaszewski M, Gu W. Using interactive platforms to encode, manage and explore immune-related adverse outcome pathways. J Immunotoxicol. 2024 Oct;21(sup1):S5-S12. doi: 10.1080/1547691X.2024.2345154. Epub 2024 Dec 10. PMID: 39655493

2022

• Donnadieu E, Luu M, Alb M, Anliker B, Arcangeli S, Bonini C, De Angelis B, Choudhary R, Espie D, Galy A, Holland C, Ivics Z, Kantari-Mimoun C, Kersten MJ, Köhl U, Kuhn C, Laugel B, Locatelli F, Marchiq I, Markman J, Moresco MA, Morris E, Negre H, Quintarelli C, Rade M, Reiche K, Renner M, Ruggiero E, Sanges C, Stauss H, Themeli M, Van den Brulle J, Hudecek M, Casucci M. Time to evolve: predicting engineered T cell-associated toxicity with next-generation models. J Immunother Cancer. 2022 May;10(5):e003486. doi: 10.1136/jitc-2021-003486. PMID: 35577500 Review.
• Guedan S, Luu M, Ammar D, Barbao P, Bonini C, Bousso P, Buchholz CJ, Casucci M, De Angelis B, Donnadieu E, Espie D, Greco B, Groen R, Huppa JB, Kantari-Mimoun C, Laugel B, Mantock M, Markman JL, Morris E, Quintarelli C, Rade M, Reiche K, Rodriguez-Garcia A, Rodriguez-Madoz JR, Ruggiero E, Themeli M, Hudecek M, Marchiq I. Time 2EVOLVE: predicting efficacy of engineered T-cells - how far is the bench from the bedside? J Immunother Cancer. 2022 May;10(5):e003487. doi: 10.1136/jitc-2021-003487. PMID: 35577501 Review.

2021

• Hayden PJ, Roddie C, Bader P, Basak GW, Bonig H, Bonini C, Chabannon C, Ciceri F, Corbacioglu S, Ellard R, Sanchez-Guijo F, Jäger U, Hildebrandt M, Hudecek M, Kersten MJ, Köhl U, Kuball J, Mielke S, Mohty M, Murray J, Nagler A, Rees J, Rioufol C, Saccardi R, Snowden JA, Styczynski J, Subklewe M, Thieblemont C, Topp M, Ispizua ÁU, Chen D, Vrhovac R, Gribben JG, Kröger N, Einsele H, Yakoub-Agha I. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol. 2022 Mar;33(3):259-275. doi: 10.1016/j.annonc.2021.12.003. Epub 2021 Dec 16. PMID: 34923107

2020

• Dragon AC, Zimmermann K, Nerreter T, Sandfort D, Lahrberg J, Klöß S, Kloth C, Mangare C, Bonifacius A, Tischer-Zimmermann S, Blasczyk R, Maecker-Kolhoff B, Uchanska-Ziegler B, Abken H, Schambach A, Hudecek M, Eiz-Vesper B. CAR-T cells and TRUCKs that recognize an EBNA-3C-derived epitope presented on HLA-B*35 control Epstein-Barr virus-associated lymphoproliferation. J Immunother Cancer. 2020 Oct;8(2):e000736. doi: 10.1136/jitc-2020-000736. PMID: 33127653

Michael Hudecek is involved as inventor in 33 patents: The list is available upon request.